Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
Go back to Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026| KARYOPHARM THERAP (NASDAQ: KPTI) | Delayed: 9.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.00 | 52 Week High | $19.41 | |||
| Open | $9.00 | 52 Week Low | $4.83 | |||
| Day High | $9.00 | P/E | N/A | |||
| Day Low | $9.00 | EPS | $-2.74 | |||
| Volume | 5 | |||||
